Invitris
Invitris is a healthcare company based in Munich, Germany, specializing in drug discovery and delivery using a technology that enhances the efficiency of drug creation and focuses on combating antibiotic-resistant infections.
Company Overview
Invitris is a healthcare company based in Munich, BY, Germany, launched in 2023. Operating within the drug discovery and delivery sub-industry, Invitris focuses on developing novel biological drugs. The team consists of six employees, and the company's innovative approach includes using a patent-pending technology platform to turn DNA into synthetic proteins. This technology significantly enhances drug creation efficiency by over 10,000 times while reducing material costs by up to 100 times.
Technology and Innovation
Invitris employs a patent-pending technology platform that converts DNA into synthetic proteins. This groundbreaking approach makes drug creation more than 10,000 times more efficient and reduces material costs by less than 100 times. The company's technological advancements are aimed at addressing significant challenges in the healthcare industry, particularly in combating antibiotic-resistant infections using synthetic bacteriophages.
Y Combinator W23 Batch
Invitris was selected as part of the prestigious Y Combinator W23 batch. This affiliation underscores the company's potential in the healthcare sector and provides them with substantial mentorship and networking opportunities. Being part of Y Combinator W23 offers Invitris a platform to further their research and development capabilities.
Locations and Work Model
Invitris is headquartered in Munich, BY, Germany, but operates across various regions including Germany, Europe, and remotely. The company supports both local and remote work environments, allowing them to cater to a diverse set of employees and collaborators. This flexibility aids in drawing top talent and enables seamless international collaboration.
Focus on Antibiotic-Resistant Infections
A significant part of Invitris's research is aimed at combating antibiotic-resistant infections. The company utilizes synthetic bacteriophages through its advanced technology to address this pressing global health issue. Invitris's efforts in this field have garnered attention and were featured in Science magazine, highlighting the importance and impact of their work.
